Please ensure Javascript is enabled for purposes of website accessibility

Could Tilray Be a Millionaire-Maker Stock?

By Zhiyuan Sun - Feb 3, 2021 at 7:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This marijuana stock once turned its early investors into multi-millionaires -- assuming they sold at the right time. Can it make investors rich again?

In 2018, Tilray (TLRY) reached the pinnacle of the Canadian marijuana craze. Within a month of its IPO, the stock shot up from $17 to $300. That monstrous rally was fueled by a short squeeze that pitted retail enthusiasts against institutional bears such as Citron Research -- not unlike what's currently happening with GameStop (GME 0.92%).

However, just when shareholders' initial investments were multiplying many times over, investors began noticing the company's lack of fundamentals and exited en masse. Now more than two years since the roller-coaster ride, Tilray's shares are down over 90% from its all-time highs. 

As it turns out, when a bubble bursts, the stock price can remain severely depressed for an extended period -- and undervalued -- even when the underlying company's fundamentals begin catching up. Market participants are wary of jumping in due to the fear of another capitulation. That said, I believe that Tilray's fundamentals are improving, and it's a matter of time the market will recognize its potential. 

Landscape of a marijuana growth field.

Image source: Getty Images.

A merger in the nick of time 

Ever since Tilray's bubble burst, its stock hasn't seen significant movement upwards, until now. The company will merge with its fellow pot grower Aphria (APHA) this year to create the world's largest cannabis producer, under Tilray's trade name. Its expected combined pro-forma annual revenue of CA$874 million will surpass the previous record set by Curaleaf (CURA -1.36%) (CURLF -0.99%) of CA$842 million. 

Tilray will integrate its expertise in medical cannabis with Aphria's diversified product line, ranging from vapes to edibles to oils and capsules. Revenue synergies aside, Aphria-Tilray also expects to save CA$100 million over the next 24 months in operating costs due to the deal. Over the past year, the two pot growers increased their operating income less non-cash expenses (EBITDA) almost 19-fold from just CA$1 million.

Of course, the bigger contributor to the combined entity is Aphria. During the second quarter of 2021 (ended Nov. 30, 2020), the company grew its revenue to CA$160.5 million from CA$120.6 million in the prior year's quarter. It also managed to turn a profit of $0.01 in earnings per share after adjustments, compared to a loss of $0.19 per share in Q2 2020. 

Aphria is making a big dent in the U.S. cannabis industry with its recent SweetWater Brewing acquisition. SweetWater manufacturers several popular craft beer brands that emulate the flavor of cannabis strains.

Its products are available in over 29,000 retail locations as well as 10,000 restaurants and bars across the nation. The company can produce 400,000 barrels of craft beer per year and manages to sell over 230,000 barrels. SweetWater is just what Aphria needs to expand southward and tackle the $20 billion U.S. marijuana industry. 

Besides, Aphria also has a sizable presence in Germany selling medical cannabis. In fact, over half of the company's revenue comes from distribution sales from its German subsidiary, CC Pharma.

Last but not least, Aphria also commands a leading position in its home country. Together with Tilray, the two giants will hold a 17.3% market share in the Canadian cannabis market, putting it in the top position by a large margin.

What's the verdict? 

Despite its accomplishments, Tilray stock is trading for about 10 times revenue, which is slightly below the industry average of 15.3 times sales. Overall, I expect Tilray to become a millionaire-maker stock once again -- and perhaps even exceed its previous all-time highs. Its shares, however, are priced in the context of a different reality than 2018. 

Back then, investors hyped up marijuana stocks based solely on their theoretical production volume. Now, however, investors are more demanding. They want to see solid revenue growth than anything else. Given that Tilray and Aphria's sales are increasing dramatically, it will take perhaps a decade or so for Tilray's stock to truly reflect the company's potential. For those with a long-term buy-and-hold mindset, it is an ideal pot stock to own.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Tilray
TLRY
GameStop Corp. Stock Quote
GameStop Corp.
GME
$123.42 (0.92%) $1.12
Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
CURLF
$5.00 (-0.99%) $0.05
Aphria Stock Quote
Aphria
APHA
Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
CURA
$6.51 (-1.36%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.